BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26274939)

  • 1. Atypical Chronic Myeloid Leukemia in Two Pediatric Patients.
    Freedman JL; Desai AV; Bailey LC; Aplenc R; Burnworth B; Zehentner BK; Teachey DT; Wertheim G
    Pediatr Blood Cancer; 2016 Jan; 63(1):156-9. PubMed ID: 26274939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
    Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
    Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
    Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
    J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
    J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
    Maxson JE; Gotlib J; Pollyea DA; Fleischman AG; Agarwal A; Eide CA; Bottomly D; Wilmot B; McWeeney SK; Tognon CE; Pond JB; Collins RH; Goueli B; Oh ST; Deininger MW; Chang BH; Loriaux MM; Druker BJ; Tyner JW
    N Engl J Med; 2013 May; 368(19):1781-90. PubMed ID: 23656643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
    Maxson JE; Luty SB; MacManiman JD; Paik JC; Gotlib J; Greenberg P; Bahamadi S; Savage SL; Abel ML; Eide CA; Loriaux MM; Stevens EA; Tyner JW
    Clin Cancer Res; 2016 Feb; 22(3):757-64. PubMed ID: 26475333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and evolving understanding of atypical chronic myeloid leukemia.
    Schwartz LC; Mascarenhas J
    Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
    Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
    Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq.
    Sheng G; Zhang J; Zeng Z; Pan J; Wang Q; Wen L; Xu Y; Wu D; Chen S
    Cancer Genet; 2017 Oct; 216-217():16-19. PubMed ID: 29025591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    Dao KT; Tyner JW; Gotlib J
    Curr Hematol Malig Rep; 2017 Oct; 12(5):432-441. PubMed ID: 28983816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's different about atypical CML and chronic neutrophilic leukemia?
    Dao KH; Tyner JW
    Hematology Am Soc Hematol Educ Program; 2015; 2015():264-71. PubMed ID: 26637732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML.
    Bartels S; Lehmann U; Büsche G; Schlue J; Hussein K; Debatin D; Karcher A; Andrulis M; Schirmacher P; Kreipe H
    Ann Hematol; 2015 Jul; 94(7):1255-6. PubMed ID: 25865944
    [No Abstract]   [Full Text] [Related]  

  • 13. [Emergence of mutation in the colony-stimulating factor 3 receptor gene during follow-up of unclassifiable myeloproliferative neoplasm].
    Harada S; Okada K; Yokoyama S; Hidaka D; Hayase E; Onozawa M; Goto H; Hashimoto D; Kahata K; Endo T; Teshima T
    Rinsho Ketsueki; 2021; 62(11):1609-1614. PubMed ID: 34866084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT.
    Langabeer SE; McCarron SL; Haslam K; O'Donovan MT; Conneally E
    Bone Marrow Transplant; 2014 Jun; 49(6):843-4. PubMed ID: 24614839
    [No Abstract]   [Full Text] [Related]  

  • 16. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.
    Ammatuna E; Eefting M; van Lom K; Kavelaars FG; Valk PJ; Touw IP
    Ann Hematol; 2015 May; 94(5):879-80. PubMed ID: 25491280
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
    Szuber N; Orazi A; Tefferi A
    Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
    Kim SY; Song IC; Kim J; Kwon GC
    Ann Diagn Pathol; 2024 Apr; 71():152317. PubMed ID: 38642470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical Chronic Myeloid Leukemia: Where Are We Now?
    Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective migration and dysmorphology of neutrophil granulocytes in atypical chronic myeloid leukemia treated with ruxolitinib.
    Bornemann L; Schuster M; Schmitz S; Sobczak C; Bessen C; Merz SF; Jöckel KH; Haverkamp T; Gunzer M; Göthert JR
    BMC Cancer; 2020 Jul; 20(1):650. PubMed ID: 32660441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.